Bris­tol-My­ers hands over $100M in cash for a new fi­bro­sis drug, beef­ing up NASH fo­cus

It’s not all check­points all the time at Bris­tol-My­ers Squibb. The big biotech has been ramp­ing up an am­bi­tious ef­fort in fi­bro­sis and NASH and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.